Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST‐elevation myocardial infarction: the international randomised open‐label ATOLL trial. The Lancet 2011; 378:693–703.92 92 Silvain J, Beygui F, Barthélémy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta‐analysis. BMJ 2012; 344:e553.
93 93 Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST‐segment elevation myocardial infarction: the OASIS‐6 randomized trial. JAMA 2006; 295:1519–30.
94 94 Group FTT'C. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. The Lancet 1994; 343:311–22.
95 95 Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317:581–8.
96 96 O'Neill WW, Weintraub R, Grines C, et al. A prospective, placebo‐controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992; 86:1710–6.
97 97 ASSENT‐4 PCI Investigators. Primary versus tenecteplase‐facilitated percutaneous coronary intervention in patients with ST‐segment elevation acute myocardial infarction (ASSENT‐4 PCI): randomised trial. The Lancet 2006; 367:569–78.
98 98 Sutton AGC, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST‐segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol 2004; 44:287–96.
99 99 Gershlick AH, Stephens‐Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005; 353:2758–68.
100 100 Desch S, Eitel I, Rahimi K, et al. Timing of invasive treatment after fibrinolysis in ST elevation myocardial infarction‐‐a meta‐analysis of immediate or early routine versus deferred or ischemia‐guided randomised controlled trials. Heart 2010; 96:1695–702.
101 101 Madan M, Halvorsen S, Di Mario C, et al. Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST‐segment elevation myocardial infarction: a patient‐level analysis of the randomized early routine invasive clinical trials. JACC Cardiovasc Interv 2015; 8:166–74.
102 102 Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142–54.
103 103 GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673–82.
104 104 van de Werf F. Single‐bolus tenecteplase compared with front‐loaded alteplase in acute myocardial infarction: the ASSENT‐2 double‐blind randomised trial. The Lancet 1999; 354:716–22.
105 105 ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group. Randomised Trial of Intervenous Streptokinase, Oral Aspirin, Both, or Neither Among 17,187 Cases of Suspected Acute Myocardial Infarction: ISIS‐2. The Lancet 1988; 332:349–60.
106 106 Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST‐segment elevation. N Engl J Med 2005; 352:1179–89.
107 107 Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST‐elevation myocardial infarction. N Engl J Med 2006; 354:1477–88.
108 108 ASSENT‐3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT‐3 randomised trial in acute myocardial infarction. The Lancet 2001; 358:605–13.
109 109 Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low‐molecular‐weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104:648–52.
110 110 The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial. J Am Coll Cardiol 1998; 32:2003–10.
111 111 Ronner E, van Kesteren HA, Zijnen P, et al. Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction; a phase II dose escalation, randomized, double‐blind study. Eur Heart J 2000; 21:1530–6.
112 112 Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99:2720–32.
113 113 Ronner E, van Domburg RT, van den Brand MJBM, et al. Platelet GP IIb/IIIa receptor blockers for failed thrombolysis in acute myocardial infarction, alone or as adjunct to other rescue therapies; single centre retrospective analysis of 548 consecutive patients with acute myocardial infarction. Eur Heart J 2002; 23:1529–37.
114 114 Denktas AE, Athar H, Henry TD, et al. Reduced‐dose fibrinolytic acceleration of ST‐segment elevation myocardial infarction treatment coupled with urgent percutaneous coronary intervention compared to primary percutaneous coronary intervention alone results of the AMICO (Alliance for Myocardial Infarction Care Optimization) Registry. JACC Cardiovasc Interv 2008; 1:504–10.
115 115 Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST‐segment elevation myocardial infarction. N Engl J Med 2013; 368:1379–87.
116 116 Pu J, Ding S, Ge H, et al. Efficacy and Safety of a Pharmaco‐Invasive Strategy With Half‐Dose Alteplase Versus Primary Angioplasty in ST‐Segment‐Elevation Myocardial Infarction: EARLY‐MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST‐Segment‐Elevation Myocardial Infarction). Circulation 2017; 136:1462–73.
117 117 Roule V, Ardouin P, Blanchart K, et al. Prehospital fibrinolysis versus primary percutaneous coronary intervention in ST‐elevation myocardial infarction: a systematic review and meta‐analysis of randomized controlled trials. Critical Care (London, England) 2016; 20:359.
118 118 Siontis KC, Barsness GW, Lennon RJ, et al. Pharmacoinvasive and Primary Percutaneous Coronary Intervention Strategies in ST‐Elevation Myocardial Infarction (from the Mayo Clinic STEMI Network). Amer J Cardiol 2016; 117:1904–10.
119 119 Carrillo X, Fernandez‐Nofrerias E, Rodriguez‐Leor O, et al. Early ST elevation myocardial infarction in non‐capable percutaneous coronary intervention centres: in situ fibrinolysis vs percutaneous coronary intervention transfer. Eur Heart J 2016; 37:1034–40.
120 120 Berwanger O, Lopes RD, Moia DDF, et al. Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial. J Am Coll Cardiol 2019; 73:2819–28.
121 121
